Tiragolumab + Atezolizumab for Non-Small Cell Lung Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This study will evaluate the safety and efficacy of tiragolumab plus atezolizumab compared with placebo plus atezolizumab in chemotherapy-naive patients with locally advanced unresectable or metastatic PD-L1-selected non-small cell lung cancer (NSCLC), excluding patients with a sensitizing EGFR mutation or ALK translocation.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
Is the combination of Tiragolumab and Atezolizumab safe for treating non-small cell lung cancer?
The combination of Tiragolumab and Atezolizumab has been studied for safety in treating non-small cell lung cancer. Atezolizumab alone has shown an acceptable safety profile, with common side effects including fatigue, decreased appetite, and nausea. Serious side effects like pneumonia and liver inflammation were less common, occurring in a small percentage of patients.12345
How is the drug combination of Tiragolumab and Atezolizumab unique for treating non-small cell lung cancer?
What data supports the effectiveness of the drug combination Tiragolumab and Atezolizumab for treating non-small cell lung cancer?
Research shows that the combination of tiragolumab and atezolizumab has shown promising results in treating non-small cell lung cancer, with significant outcomes in early trials. Atezolizumab alone has been effective in treating various cancers, including bladder cancer, and is approved for use in non-small cell lung cancer, suggesting potential benefits when combined with tiragolumab.147910
Who Is on the Research Team?
Clinical Trials
Principal Investigator
Hoffmann-La Roche
Are You a Good Fit for This Trial?
This trial is for adults with advanced non-small cell lung cancer (NSCLC) that hasn't been treated with chemotherapy. Participants must have tumors expressing PD-L1, a life expectancy of at least 12 weeks, and good organ function. They should not be pregnant or breastfeeding, agree to use contraception, and have no history of certain diseases like autoimmune disorders or severe allergies to specific antibodies.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive atezolizumab and either tiragolumab or placebo by IV infusion every 3 weeks
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Atezolizumab
- Tiragolumab
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
Genentech, Inc.
Lead Sponsor
Ashley Magargee
Genentech, Inc.
Chief Executive Officer since 2024
MBA from Harvard University, BA from Princeton University
Levi Garraway
Genentech, Inc.
Chief Medical Officer since 2021
MD, PhD